VICTORIA, British Columbia, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology...
Data highlights ability of Akari’s ADC payload, PH1, to suppress the levels of the AR-V7 receptor that is responsible for...
Sapu003 Designed to Overcome Limitations of Afinitor®, FDA-Approved Oral Everolimus, by Delivering Full Strength of the Drug via Intravenous InjectionSAN...
Funding supports Phase 2b development of clofutriben, a novel HSD-1 inhibitor, with a focus on cortisol-driven metabolic dysfunction in type...
BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company...
Intends to Initiate Phase 1b Clinical Trial in TNBC at Mayo Clinic in Fourth Quarter 2025FLORHAM PARK, N.J. and LONDON...
Ritedose Lab Expansion Ritedose is growing in laboratory and drug development capacity - with the announcement of a $17M in-house...
THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line...
Company honored in its commitment to patients and families living with mitochondrial disease; invites the community to walk with BPGbio...
Engagement Will Expand Daré’s Engagement in Advancing Women’s Health Innovation and Provide Insights into One of the Most Significant Unmet...
TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and...
Program to Provide Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for Applications is...
~ Term of current $50 million debt outstanding extended from January 2027 to October 2030 ~ ~ Additional $100 million...
IMDX to host symposium on Wednesday, September 24th to discuss GraftAssureIQ™ at International Association of Therapeutic Drug Monitoring and Clinical...
~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by...
FG-3246 Phase 2 dose optimization trial to enroll 75 patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-androgen receptor...
- Update based on FDA End-of- Phase 2 meeting outcome - Phase 3 study start accelerated by six months, in...
SAN MATEO, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing...
Clinically significant angiokeratomas are characterized by lymphatic-derived skin lesions that can persistently bleed and significantly impact quality-of-life; no FDA-approved therapies...
TOKYO and GUANGZHOU, China, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd. (Riken Genesis) and Burning Rock Biotech...